| Serial Number | 79291480 |
| Word Mark | NANOPRIMER |
| Filing Date | Wednesday, June 24, 2020 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 20, 2021 |
| Registration Number | 6422329 |
| Registration Date | Tuesday, July 20, 2021 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, May 4, 2021 |
| Description of Mark | The mark consists of the following: the stylized wording "NANOPRIMER" in white against a blue background. |
| Goods and Services | Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalance, metabolic brain diseases, disorders of calcium metabolism, DNA repair-deficiency disorders, glucose metabolism disorders, hyperlactatemia, iron metabolism disorders, lipid metabolism disorders, malabsorption syndromes, metabolic syndrome X, inborn error of metabolism, mitochondrial diseases, phosphorus metabolism disorders, porphyrias, proteostasis deficiencies, metabolic skin diseases, wasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver disease, non-alcoholic fatty liver disease, hepatitis, haemochromatosis, primary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicines, monoclonal antibodies, antibody-drug conjugates, small molecules, and to prevent and treat Gaucher's disease, mastocytosis, and histiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acid, small molecules, proteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; drugs for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; medicines for human to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; tonics for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection |
| Indication of Colors claimed | The color(s) white and blue is/are claimed as a feature of the mark. |
| Goods and Services | Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy |
| Goods and Services | Scientific and technological services as well as, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering work, namely, surveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnology, especially applied to medicine |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 14, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 14, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 14, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Curadigm |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 34 - NOT AVAILABLE |
| Address | FR |
| Party Name | Curadigm |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 34 - NOT AVAILABLE |
| Address | FR |
| Party Name | Curadigm |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 34 - NOT AVAILABLE |
| Address | FR |
| Event Date | Event Description |
| Thursday, November 5, 2020 | REFUSAL PROCESSED BY MPU |
| Thursday, August 13, 2020 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, August 14, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, August 18, 2020 | APPLICATION FILING RECEIPT MAILED |
| Sunday, September 27, 2020 | ASSIGNED TO EXAMINER |
| Saturday, October 17, 2020 | NON-FINAL ACTION WRITTEN |
| Sunday, October 18, 2020 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Sunday, November 29, 2020 | REFUSAL PROCESSED BY IB |
| Friday, November 6, 2020 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, January 18, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, January 18, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 19, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, March 26, 2021 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Friday, March 26, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Friday, March 26, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, March 26, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, March 26, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, March 26, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Friday, March 26, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, May 4, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, April 14, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, April 14, 2021 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, April 14, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Sunday, May 2, 2021 | NOTIFICATION PROCESSED BY IB |
| Tuesday, May 4, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 20, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, October 20, 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Wednesday, November 17, 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| Wednesday, November 17, 2021 | FINAL DISPOSITION PROCESSED |
| Monday, December 13, 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Saturday, December 4, 2021 | CHANGE OF NAME/ADDRESS REC'D FROM IB |